Crinetics’ Palsonify: A New Era in Acromegaly Treatment – First-of-its-Kind Oral Therapy Approved by FDA
for decades, managing acromegaly – a rare hormonal disorder caused by excessive growth hormone – has been a significant clinical challenge. Patients have largely relied on injectable therapies, frequently enough facing adherence issues and limited efficacy. Now, a paradigm shift is underway with the FDA approval of Palsonify (osilocane), a first-in-class, once-daily oral medication developed by Crinetics Pharmaceuticals. this approval marks a pivotal moment,offering a perhaps more convenient and effective treatment option for individuals grappling with this complex condition.
Understanding Acromegaly and the Existing Treatment Landscape
Acromegaly arises from a pituitary tumor that produces too much growth hormone, leading to a range of debilitating symptoms including enlarged hands and feet, facial changes, joint pain, and increased risk of cardiovascular disease and diabetes.Effective management hinges on normalizing growth hormone and insulin-like growth factor 1 (IGF-1) levels - achieving what clinicians term “biochemical control.”
historically, treatment has involved surgery, radiation therapy, and medications. The existing pharmacological options primarily consist of somatostatin analogs (SSAs). Until recently, the only oral SSA available was Chiesi FarmaceuticiS Mycapssa (octreotide), approved in 2020. Though, Mycapssa’s approval was specifically limited to maintenance therapy for patients already responding to injectable SSAs from Novartis and Ipsen. For those who don’t respond, or experience disease progression, injectable growth hormone receptor antagonists remain the primary alternative.
This landscape has been fraught with limitations. Research consistently demonstrates that existing peptide drugs frequently enough fall short of achieving consistent biochemical control and adequately managing the diverse symptoms of acromegaly. Furthermore, patient adherence to injectable therapies can be problematic, contributing to suboptimal outcomes. Crinetics estimates that a substantial 80% of patients on injectable acromegaly drugs discontinue or switch therapies within five years, highlighting a clear unmet need.
Palsonify: clinical Trial Results Demonstrate Superior Efficacy and Tolerability
Palsonify addresses this need with a novel approach. It’s a selective agonist of the somatostatin receptor subtype 2 (SST2), designed for optimal efficacy and convenience. Robust Phase 3 clinical trial data underpin its approval:
* First Trial (111 adult patients): A remarkable 56% of patients receiving Palsonify achieved biochemical control at 24 weeks, compared to just 5% in the placebo group. This represents a significant improvement in treatment response.
* Second Trial (58 previously treated adults): Switching to Palsonify resulted in biochemical control maintenance in 86% of patients at 36 weeks, a stark contrast to the 4% maintenance rate observed in the placebo arm. This suggests Palsonify is effective not only in initiating control but also in sustaining it.
Importantly, Palsonify demonstrated a favorable safety profile. No serious adverse events were reported during the trials. The most common side effects – nausea, diarrhea, and loss of appetite – were generally mild to moderate in severity and resolved within 6-18 days. Moreover, the drug did not lead to clinically significant increases in tumor volume; actually, four patients experienced clinically significant tumor shrinkage.
A Competitive Price point and a Strategic Market Position
Crinetics has priced Palsonify at an annual list price of $290,000, positioning it competitively within the existing acromegaly treatment market. Isabel Kalofonos,Chief Commercial Officer at Crinetics,emphasizes that this price aligns with other available therapies.
The company anticipates a gradual launch in early October, acknowledging the need for patients to schedule appointments with their physicians for consultation and potential prescription. However, analysts are optimistic about Palsonify’s potential to capture significant market share. Leerink Partners analyst joseph Schwartz, in a note to investors, likened Crinetics’ entry into the acromegaly space to the biblical story of David and Goliath, suggesting the company is poised to challenge established pharmaceutical giants.
Beyond Acromegaly: Future growth Potential
Crinetics’ ambitions extend beyond acromegaly. The company is actively pursuing expansion of Palsonify’s indications. A Phase 3 study is currently underway evaluating its efficacy in carcinoid syndrome associated with neuroendocrine tumors, potentially opening up a new avenue for treatment.
Furthermore, Crinetics is exploring the drug’s potential in Japan through a partnership with Sanwa Kagaku Kenkyuso. Regulatory
Keep reading